# US 2002/0001576 A1 · Compositions comprising, as the main ingredient, allogenic activated-c4+ cells and method for producing and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001576 A1
- Document ID: US20020001576A1
- Status: Published application
- Kind: A1
- Application number: 09/288,234
- Filed: 1999-04-08
- Published: 2002-01-03
- Earliest claimed: 1998-04-09
- Assignees: Teruaki Sekine
- Inventors: TERUAKI SEKINE; KIMINARI ITO; KENZO BAMBA; YASUYUKI KUROIWA
- Web page: https://patentgrep.com/patent/US20020001576A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- C12N 2501/23: Interleukins [IL]
- C12N 2501/515: CD3, T-cell receptor complex
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Medicaments or preparations containing allogenic activated-CD4+ cells as the main ingradient, which are attributable to an organ or bone marrow transplantation donor, have an extremely beneficial effect for preventing recidivation of a tumor and remedying various infections such as viral infections, and autoimmune diseases such as phagocytosis, without causing any serious GVHD. The allogenic activated-CD4+ cells can be produced by separating lymphocyte cells or CD4+ cells from peripheral blood of the donor or removing CD8+ cells from the peripheral blood of the donor by using anti-CD8+ antibodies to obtain CD4+ cells and proliferating the CD4+ cells thus prepared in a proliferation activator.

## Claims

### Claim 1

Medicaments or preparations containing, as their main ingradient, allogenic activated-CD4+ cells.

### Claim 2 (depends on 1)

Medicaments or preparations set forth in claim 1, prepared for restraining recidivation of a tumor.

### Claim 3 (depends on 1)

Medicaments or preparations set forth in claim 1, prepared for remedying infections.

### Claim 4 (depends on 1)

Medicaments or preparations set forth in claim 1, prepared for remedying viral infections.

### Claim 5 (depends on 1)

Medicaments or preparations set forth in claim 1, prepared for remedying autommune diseases.

### Claim 6 (depends on 1)

Medicaments or preparations set forth in claim 1, wherein said allogenic activated-CD4+ cells are attributable to activated-CD4+ cells of an organ or bone marrow transplantation donor.

### Claim 7 (depends on 1)

Medicaments or preparations set forth in claim 1, containing 90% or more of allogenic activated-CD4+ cells in number relative to all cells contained therein.

### Claim 8 (depends on 1)

Medicaments or preparations set forth in claim 1, containing 10% or less of activated-CD8+ cells in number relative to all cells contained therein.

### Claim 10

Medicaments o allogenic activated-CD4+ cells as their main ingradient, said activated-CD4+ cells being prepared by separating lymphocyte cells or CD4+ cells from peripheral blood of a donor, and proliferating said CD4+ cells prepared.

### Claim 11

A medical kit for preparing medicaments or preparations containing allogenic activated-CD4+ cells as their main ingradient.

### Claim 12

A medical kit for preparing medicaments or preparations containing allogenic activated-CD4+ cells prepared by using solidified carriers of anti-CD4 antibodies, interleukin-2, and/or anti-CD3 antibodies.

### Claim 13

A method for producing medicaments or preparations containing, as their main ingradient, allogenic activated-CD4+ cells, comprising separating CD4+ cells from peripheral blood of a donor, and proliferating said CD4+cells prepared in a proliferation activator to obtain and add said allogenic activated-CD4+ cells to said medicaments or preparations.

### Claim 14 (depends on 13)

A method set forth in claim 13, wherein said proliferation activator is made of interleukin-2 and/or anti-CD3 antibodies.

### Claim 15 (depends on 13)

A method set forth in claim 13, wherein said allogenic activated-CD4+ cells are derived from an organ donor or bone-marrow donor.

### Claim 16

A method for producing medicaments or preparations containing, as their main ingradient, allogenic activated-CD4+ cells, comprising removing CD8+ cells from peripheral blood of a donor by using anti-CD8+antibodies to obtain CD4+ cells, and proliferating said CD4+ cells prepared in a proliferation activator to obtain and add said allogenic activated-CD4+ cells to said medicaments or preparations.

### Claim 17 (depends on 16)

A method set forth in claim 16, wherein said proliferation activator is made of interleukin-2 and/or anti-CD3 antibodies.

### Claim 18 (depends on 16)

A method set forth in claim 16, wherein said allogenic activated-CD4+ cells are derived from an organ donor or bone-marrow donor.

### Claim 19

A method for producing medicaments or preparations containing, as their main ingradient, allogenic activated-CD4+ cells, comprising proliferating allogenic lymphocyte cells in a proliferation activator, and separating activated-CD4+ cells from said allogenic lymphocyte cells by using anti-CD4+antibodies to obtain and add said allogenic activated-CD4+ cells to said medicaments or preparation.

### Claim 20 (depends on 19)

A method set forth in claim 19, wherein said proliferation activator is made of interleukin-2 and/or anti-CD3 antibodies.

### Claim 21 (depends on 19)

A method set forth in claim 19, wherein said allogenic activated-CD4+ cells are derived from an organ donor or bone-marrow donor.

### Claim 22

A method for producing medicaments or preparations containing, as their main ingradient, allogenic activated-CD4+ cells, comprising proliferating allogenic lymphocyte cells in a proliferation activator, and separating activated-CD8+ cells from said allogenic lymphocyte cells by using anti-CD8+antibodies to obtain and add said allogenic activated-CD4+ cells to said medicaments or preparation.

### Claim 23 (depends on 22)

A method set forth in claim 22, wherein said proliferation activator is made of interleukin-2 and/or anti-CD3 antibodies.

### Claim 24 (depends on 22)

A method set forth in claim 22, wherein said allogenic activated-CD4+ cells are derived from an organ donor or bone-marrow donor.
